Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Blood blood.2025029572.

https://doi.org/10.1182/blood.2025029572

Published: 2025

Includes: Supplemental data

Journal Articles

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

Blood (2025) 146 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2025-3927

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2024-205481

Published: 2024

Journal Articles

The Evaluation of a Point-of-Care Hematology Analyzer Hemoscreen for Abnormal Blood Samples

Katarina Hradska, Martin Pulcer, Michaela Skorupova, Tereza Popkova, Veronika Kelbichova, Martin Augustynek, Roman Hajek

Blood (2024) 144 (Supplement 1): 7632.

https://doi.org/10.1182/blood-2024-205824

Published: 2024

Journal Articles

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Tomas Jelinek, Serafim Nenarokov, Tereza Sevcikova, Eva Radova, Ondrej Venglar, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Ludmila Muronova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Bachisio Ziccheddu, Benjamin Diamond, Francesco Maura, Ola Landgren, David Zihala, Roman Hájek

Blood (2024) 144 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2024-206825

Published: 2024

Journal Articles

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Martin Stork, Jakub Radocha, Tomas Jelinek, Ivan Spicka, Tomas Pika, Alexandra Jungova, Jan Straub, Jiri Minarik, Ivanna Boichuk, Dominik Fric, Denisa Novakova, Tereza Popkova, Lenka Polcerova, Vladimir Maisnar, Ludek Pour, Roman Hajek

Blood (2024) 144 (Supplement 1): 5156.

https://doi.org/10.1182/blood-2024-202002

Published: 2024

Journal Articles

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

Ondrej Venglar, Eva Radova, David Zihala, Ivana Tvrda, Ludmila Muronova, Veronika Kapustova, Lucie Broskevicova, Jan Vrana, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Tereza Sevcikova, Michal Kascak, Milan Navratil, Zdenek Koristek, Roman Hajek, Tomas Jelinek

Blood (2024) 144 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2024-204692

Published: 2024

Journal Articles

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Tereza Popkova, Jakub Radocha, Martin Stork, Jiří Minařík, Jan Straub, Alexandra Jungova, Petr Pavlicek, Tomas Jelinek, Vladimir Maisnar, Ludek Pour, Tomas Pika, František Sedlák, Jan Soukup, Hana Plonkova, Ludmila Muronova, Viera Sandecka, Petra Krhovska, David Zihala, Roman Hajek

Blood (2024) 144 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2024-211224

Published: 2024

Journal Articles

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Blood (2024) 144 (Supplement 1): 1887.

https://doi.org/10.1182/blood-2024-206798

Published: 2024

Journal Articles

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Tomas Jelinek, David Zihala, Tereza Sevcikova, Veronika Kapustova, Hana Sahinbegovic, Anjana Anilkumar Sithara, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Juli R. Bago, Michal Simicek, Roman Hajek

Blood (2021) 138 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2021-150876

Published: 2021

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

David Zihala, Tereza Sevcikova, Michal Simicek, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Juli R. Bago, Roman Hajek, Giovanni Stracquadanio, Tomas Jelinek

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-142300

Published: 2020

Journal Articles

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Alexander Vdovin, Michal Durech, PhD, Tomas Jelinek, Tereza Sevcikova, PhD, Juli R. Bago, Matous Hrdinka, PhD, David Zihala, Renata Snaurova, Hana Sahinbegovic, Tereza Popkova, Ryszard Smolarczyk, PhD, Tomasz Cichon, PhD, Sebastian Giebel, MDPhD, Roman Hajek, MD PhD, Michal Simicek, PhD

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-140673

Published: 2020

Journal Articles

Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience

Ludmila Muronova, Martin Havel, MD PhD, Tereza Popkova, Hana Plonkova, Roman Hajek, Tomas Jelinek

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142369

Published: 2020

Journal Articles

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Tereza Popkova, MD, Katarina Hradska, MD, Jana Mihalyova, MD, Michaela Skorupova, Tomas Jelinek, MD, Juraj Duras, MD, Zdenek Koristek, MD PhD, Milan Navratil, MD, Katerina Benkova, MD, Hana Plonkova, MD, Jana Zuchnicka, MD, Jaromir Gumulec, MD, Roman Hajek, Prof, MD PhD

Blood (2019) 134 (Supplement_1): 4757.

https://doi.org/10.1182/blood-2019-127011

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs

Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

The Evaluation of a Point-of-Care Hematology Analyzer Hemoscreen for Abnormal Blood Samples

Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Teclistamab in Relapsed and Refractory Multiple Myeloma Patients - Czech Multi-Center Real World Evidence Analysis

Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients

A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma

Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients

Prognostic Value of PET/CT Performed Day +100 Post Autologous Stem Cell Transplantation in Multiple Myeloma: Real-World Single Center Experience

Towards Higher Safety of Haemato-Oncological Patients Undergoing Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only